United States securities and exchange commission logo





                             August 17, 2021

       Bala Venkataraman
       Chief Executive Officer
       Amplitude Healthcare Acquisition Corporation
       1177 Avenue of the Americas, Fl 40
       New York, NY 10036

                                                        Re: Amplitude
Healthcare Acquisition Corporation
                                                            Amendment No. 2 to
Registration Statement on Form S-4
                                                            Filed August 9,
2021
                                                            File No. 333-256875

       Dear Mr. Venkataraman:

            We have reviewed your amended registration statement and have the
following
       comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Amendment No. 2 to Registration Statement on Form S-4

       Summary of the Proxy Statement/Prospectus
       Jasper, page 22

   1.                                                   From your disclosure on
pages 197 and 199, it appears that your clinical trial for JSP191
                                                        for the treatment of
MDS/AML is an ongoing Phase 1 trial that is currently enrolling a
                                                        Phase 1b dose expansion
and your clinical trial for JSP191 for the treatment of SCID is an
                                                        ongoing Phase 1/2 trial
that will complete enrollment by the end of 2022. Given that
                                                        disclosure, it appears
that you should revise the pipeline table here and on page 189 to
                                                        shorten the
corresponding boxes to no longer than the middle of Phase 1, rather than the
                                                        end of Phase 1, for the
MDS/AML trial and the beginning of Phase 2, rather than the end
                                                        of Phase 2, for the
SCID trial. Please also review the current status of your product
                                                        candidates that are
shown in the pipeline table to have completed the preclinical phase and
                                                        revise the pipeline
table as appropriate. We also note that your milestone column indicates
 Bala Venkataraman
Amplitude Healthcare Acquisition Corporation
August 17, 2021
Page 2
      that the next milestone for JSP191 for the treatment of MDS/AML is
completion of study
      enrollment of a Phase 1/2 trial. Please revise or advise.
       You may contact Christie Wong at 202-551-3684 or Brian Cascio at
202-551-3676 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Ada D. Sarmento at 202-551-3798 or Christopher Edwards at 202-551-6761
with any
other questions.



                                                         Sincerely,
FirstName LastNameBala Venkataraman
                                                     Division of Corporation
Finance
Comapany NameAmplitude Healthcare Acquisition Corporation
                                                     Office of Life Sciences
August 17, 2021 Page 2
cc:       Christopher D. Barnstable-Brown, Esq.
FirstName LastName